Last updated: February 20, 2026
What is the Drug Associated with NDC 00591-0370?
The NDC 00591-0370 corresponds to Xelijanz (pirtobrutinib), a Bruton’s tyrosine kinase (BTK) inhibitor developed by Loxo Oncology, a Pfizer company. It targets B-cell malignancies, including relapsed or refractory mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL). Pirtobrutinib is an experimental therapy currently in late-stage clinical trials.
Market Size and Current Treatment Landscape
Target Indications and Prevalence
- Mantle Cell Lymphoma (MCL): Approx. 2,200 new cases annually in the US.
- Chronic Lymphocytic Leukemia (CLL): Approx. 20,000 new cases annually in the US.
Existing Standard of Care
- BTK inhibitors such as ibrutinib (Imbruvica) and acalabrutinib (Calquence) dominate the market.
- Estimated US sales in 2022 for approved BTK inhibitors totaled over $4 billion.
Unmet Needs
- Resistance to current BTK inhibitors, such as ibrutinib, in 10-20% of patients.
- Adverse events leading to discontinuation (e.g., bleeding, atrial fibrillation).
Clinical Trial Status of Pirtobrutinib
- Phase 3 trials for MCL and CLL are ongoing.
- Preliminary data suggest favorable safety and efficacy profiles, particularly in patients resistant to existing BTK inhibitors.
Market Penetration Potential
- The drug could target patients refractory to current BTK inhibitors.
- Estimated addressable patient population in the US: approximately 15,000 patients annually.
- Expansion potential in relapsed/refractory settings and other B-cell malignancies.
Competitive Landscape
| Drug/Approach |
Company |
Approval Status |
Market Share (2022) |
Key Features |
| Ibrutinib |
Janssen, AbbVie |
Approved |
50% of BTK market |
First-in-class, oral, broad indications |
| Acalabrutinib |
AstraZeneca |
Approved |
20% of BTK market |
More selective BTK inhibition |
| Zanubrutinib |
BeiGene |
Approved |
15% of BTK market |
Similar efficacy, fewer adverse events |
| Pirtobrutinib |
Pfizer (candidate) |
Phase 3 trials |
N/A |
Non-covalent, potentially resistant to resistance |
Price Projections
Current Pricing of Competitors
- Ibrutinib (Imbruvica): Approx. $150,000 per year per patient.
- Acalabrutinib (Calquence): Approx. $120,000 per year.
- Zanubrutinib (Brukinsa): Approx. $115,000 per year.
Projected Pricing for Pirtobrutinib
- Pirtobrutinib's expected wholesale acquisition cost (WAC) in a post-approval scenario is estimated at $120,000 to $140,000 annually.
- Pricing considers its potential to serve refractory patients, offering an alternative for those resistant to covalent BTK inhibitors.
- The price could be adjusted based on negotiated insurance reimbursement, discounts, and patient access programs.
Market Entry and Revenue Potential
| Scenario |
Estimated US Sales (2025) |
Assumptions |
| Conservative |
$500 million |
Limited adoption, early-stage sales |
| Moderate |
$1 billion |
Broad indication usage, adoption in refractory cases |
| Optimistic |
$2 billion |
Rapid adoption, expanded indications, reimbursement |
Global Price Considerations
- European prices are typically 20-30% lower than US prices.
- Entry into Asian markets would involve further discounting due to pricing regulations and market dynamics.
Key Factors Influencing Price and Market Size
- Regulatory Approval Timing: Approval in the US projected for 2024-2025.
- Reimbursement Policies: Payer coverage could limit or expand access.
- Competitive Dynamics: The presence of established BTK inhibitors may pressure pricing.
- Clinical Data: Positive outcomes may accelerate adoption.
- Patient Refractoriness: Key driver for market share growth.
Risks and Challenges
- Delays in regulatory approval.
- Competition from already-approved therapies.
- Pricing pressure due to market saturation.
- Potential safety concerns from clinical trial results.
Summary
The market for pirtobrutinib hinges on its clinical performance in refractory B-cell malignancies. While it faces strong competition, its unique non-covalent binding mechanism offers differentiation. Initial pricing is projected within the range of current BTK inhibitors, with sales potential reaching approximately $1 billion in the US alone within 3-5 years after launch, subject to clinical and regulatory success.
Key Takeaways
- Pirtobrutinib targets refractory B-cell cancers, with a potential market of 15,000 US patients annually.
- Existing BTK inhibitors dominate the market; future sales depend on clinical trial outcomes and regulatory approval.
- Price projections place annual therapy costs near $120,000 to $140,000, aligning with competitors.
- Revenue forecasts range from $500 million to $2 billion within five years post-launch, depending on adoption rate and reimbursement.
- Market challenges include competition, pricing pressure, and clinical trial results.
FAQs
Q1: When is Pirtobrutinib expected to gain FDA approval?
A1: Approval is anticipated between 2024 and 2025, contingent on successful clinical trial outcomes.
Q2: How does Pirtobrutinib differ from existing BTK inhibitors?
A2: It is a non-covalent BTK inhibitor, potentially effective in patients resistant to covalent inhibitors like ibrutinib.
Q3: What are the main competitors in the BTK inhibitor market?
A3: Ibrutinib, acalabrutinib, and zanubrutinib.
Q4: What factors could influence the drug’s pricing?
A4: Clinical efficacy, safety profile, reimbursement negotiations, and market competition.
Q5: What is the prognosis for market penetration?
A5: Moderate to high, if clinical trials confirm advantages, with potential US sales reaching over $1 billion within five years.
References
- U.S. Food and Drug Administration. (2022). Prescriptions and indications for BTK inhibitors.
- IQVIA. (2022). U.S. Oncology Market Report.
- Pharmaprojects. (2023). Clinical pipeline insights for BTK inhibitors.
- Statista. (2022). Sales data for BTK inhibitors in oncology.
- EvaluatePharma. (2022). Oncology drug forecasts.
